Seagen Inc. (SGEN) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Bothell, WA, United States. Le PDG actuel est David R. Epstein.
SGEN a date d'introduction en bourse 2001-03-09, 3,256 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $43.15B.
Seagen Inc. is a biotechnology company headquartered in Bothell, Washington, specializing in the development and commercialization of cancer therapies. The company's commercial portfolio includes ADCETRIS for Hodgkin lymphoma and CD30-positive T-cell lymphomas, PADCEV for advanced urothelial cancer, and TUKYSA for HER2-positive breast cancer, alongside several pipeline candidates such as TIVDAK for cervical cancer and multiple novel antibody-drug conjugates targeting various oncology indications. Seagen operates globally and maintains strategic collaboration agreements with leading pharmaceutical companies including Takeda, Merck, and Genmab. The company was founded in 1997 as Seattle Genetics and rebranded as Seagen Inc. in 2020.
